Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Retinal Disease Therapeutics Market Worth US$ 21,318.0 Mn by Top International Players as Merck, Novartis, Allergan, Roche & More Forecast 2026

Retinal Disease Therapeutics Market 2019 Industry Overview, Key Players Analysis, Emerging Opportunities Forecast 2026

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/25/2019 -- The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled "Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026," the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.

Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311

The global retinal disease therapeutics market is consolidated in nature, with only a handful of market players accounting for maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success.Therefore the global market is boosted by products and concepts introduced by existing companies.

Some of the Main Key Players Covered in the Report

- Merck
- Novartis
- Allergan
- Roche
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical

F. Hoffmann-La Roche AG's 'Lucentis' is Gaining Increasing Popularity

The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).

One such instance of this development is the "Lucentis" therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced with the aim of providing therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.

Excellent clinical effects of Lucentis have led to a subsequent rise in demand for medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Recent industry developments such as mergers & acquisitions
4.2 Regulatory scenario for key countries
4.3 Prevalence of Key Retinal Diseases, in Major Countries
5. Global Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2 Market Analysis, Insights and Forecast – By Disease Indication
5.2.1 Macular Degeneration
5.2.2 Diabetic Macular Edema
5.2.3 Diabetic Retinopathy
5.2.4 Retinal Vein Occlusion
5.2.5 Others
5.3. Market Analysis, Insights and Forecast – By End User
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1 North America
5.4.2 Europe
5.4.3 Asia Pacific
5.4.4 Latin America
5.4.5 Middle East & Africa

North America to Emerge Dominant in the Forecast Period

The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.

Improved health infrastructures, increasing patient pool, and favourable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in Asia Pacific is a major reason, why this region is estimated to rise with the highest CAGR in the forecast period.

Get Customization:
https://www.fortunebusinessinsights.com/enquiry/customization/retinal-disease-therapeutics-market-100311

For more information on this press release visit: http://www.sbwire.com/press-releases/retinal-disease-therapeutics-market-worth-us-213180-mn-by-top-international-players-as-merck-novartis-allergan-roche-more-forecast-2026-1237862.htm

Media Relations Contact

Ashwin Arora
sales manager
Fortune Business Insights
Telephone: 4242530390
Email: Click to Email Ashwin Arora
Web: https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

Latest News
Top News